Background-Congestive heart failure (CHF) is associated with a change in cardiac energy metabolism. However, the mechanism by which this change is induced and causes the progression of CHF is unclear. Methods and Results-We analyzed the cardiac energy metabolism of Dahl salt-sensitive rats fed a high-salt diet, which showed a distinct transition from compensated left ventricular hypertrophy to CHF. Glucose uptake increased at the left ventricular hypertrophy stage, and glucose uptake further increased and fatty acid uptake decreased at the CHF stage. The gene expression related to glycolysis, fatty acid oxidation, and mitochondrial function was preserved at the left ventricular hypertrophy stage but decreased at the CHF stage and was associated with decreases in levels of transcriptional regulators. In a comprehensive metabolome analysis, the pentose phosphate pathway that regulates the cellular redox state was found to be activated at the CHF stage. Dichloroacetate (DCA), a compound known to enhance glucose oxidation, increased energy reserves and glucose uptake. DCA improved cardiac function and the survival of the animals. DCA activated the pentose phosphate pathway in the rat heart. DCA activated the pentose phosphate pathway, decreased oxidative stress, and prevented cell death of cultured cardiomyocytes. Conclusions-Left ventricular hypertrophy or CHF is associated with a distinct change in the metabolic profile of the heart.
C ongestive heart failure (CHF) is associated with a significant change in energy metabolism of the heart, and the altered energetics is hypothesized to play an important role in the progression of CHF. 1 Cardiac energy metabolism consists of 3 main components. 2 The first is substrate utilization that includes the uptake and metabolism of fatty acids and carbohydrate (glucose and lactate) and the entry of the resulting intermediates into the tricarboxylic acid (TCA) cycle. Several studies have analyzed substrate utilization in failing hearts, with conflicting results. 3 The second component is oxidative phosphorylation in the mitochondria to produce ATP with reduced nicotinamide adenine dinucleotide produced by the TCA cycle. Energy production and oxygen consumption decrease when associated with a decrease in activities of the respiratory chain and ATP synthase. 4 The third component is the transfer of ATP from the mitochondria to the myofibrils by the creatine kinase system. Creatine kinase activity and phosphocreatine (PCr) decrease in patients with CHF. 5 The ratio of PCr to ATP, a marker of the energetic state of the heart, is correlated with the symptoms or prognosis of patients with CHF. 2 
Clinical Perspective on p 430
Among the changes in energy metabolism associated with CHF, modulation of substrate utilization seems to be a promising target of intervention. 3 Dichloroacetate (DCA) is a chemical that inhibits pyruvate dehydrogenase (PDH) kinase, thereby stimulating PDH and carbohydrate oxidation. Since its discovery in 1969, DCA has been used to treat lactic acidosis complications of congenital mitochondrial diseases and diabetes. 6, 7 Recently, it has been suggested that DCA may be useful for treating pulmonary hypertension or cancer. 8, 9 DCA improves cardiac function after ischemia in ex vivo perfused hearts. 10 The effects of short-term administration of DCA on left ventricular performance have been studied in patients with CHF, with conflicting results. 11, 12 Despite all research efforts, the mechanism by which the alteration of cardiac energy metabolism is induced and causes progression of CHF is unclear. One reason for this is that current knowledge is based on studies analyzing different parameters of metabolism in different animal models or in patients with different clinical backgrounds. Thus, we simultaneously analyzed cardiac function, substrate uptake, cardiac energy reserve, gene and protein expression, and amounts of metabolites by metabolome analysis in a rat model of CHF that shows a distinct transition from compensated left ventricular hypertrophy (LVH) to CHF. The effect of long-term treatment with DCA on this transition was also analyzed to examine the role of glucose metabolism in the progression of CHF.
Methods
See the online-only Data Supplement for additional details.
Animals
Inbred male Dahl salt-sensitive (DS) rats were fed a 0.3% NaCl (low salt; LS) diet until the age of 6 weeks, after which they were fed an 8% NaCl (high salt; HS) diet. 13 DS rats that were fed an LS diet were used as controls. At 11 weeks of age, the rats fed an HS or LS diet were randomly assigned to groups to receive either vehicle or DCA (Sigma-Aldrich Co, St. Louis, Mo) at a dose of 80 mg/(kg ⅐ d) in drinking water. 8 Animal care and the experiments were approved by the institutional animal care and use committee of Kyoto University.
Statistical Analysis
Values are expressed as meansϮSEM. The survival of the animals was analyzed by the Kaplan-Meier method with a log-rank test. Nonparametric analysis with Dunn's procedure was used to analyze metabolome data. Other data were analyzed by ANOVA followed by post hoc comparisons with the Bonferroni test. When there were 2 crossed factors, differences between groups were analyzed by 2-way factorial ANOVA followed by post hoc comparisons with the Bonferroni test. In all tests, a value of PϽ0.05 was considered significant.
Results

Transition From LVH to CHF in Dahl Rats
As we reported previously, DS rats that were fed an HS diet developed hypertension at 11 weeks of age (supplemental Table I ). 13 On echocardiographic examination, left ventricular posterior wall thickness was significantly increased and fractional shortening was preserved in DS rats at 11 weeks of age, indicating the establishment of concentric LVH ( Figure  1A and supplemental Table II ). At Ϸ17 weeks of age, the DS rats that were fed an HS diet showed signs of CHF and showed decreased fractional shortening.
Myocardial Energy Reserve Measured by In Situ
P Magnetic Resonance Spectroscopy
We analyzed the change in cardiac energy reserves during the transition from cardiac hypertrophy to heart failure by measuring cardiac high-energy phosphates with in situ 31 P magnetic resonance spectroscopy. The cardiac PCr/ATP decreased by 12% at the LVH stage and by 42% at the CHF stage, compared with that for control rats ( Figure 1B and Online Supplemental Figure I ).
Myocardial Uptake of Glucose and Fatty Acids
To estimate the change in substrate utilization during the transition from LVH to CHF, we examined the myocardial uptake of glucose and fatty acids by using 18 F-deoxyglucose (FDG) and 125 I-15-(p-iodophenyl)-9-R,S-methylpentadecanoic acid (9MPA), respectively ( Figure 1C and 1E and supplemental Table III ). 14 In DS rats that were fed an HS diet, the uptake of 18 FDG increased by 1.4-fold at the LVH stage and by 2.4-fold at the CHF stage compared with the levels in control rats fed an LS diet ( Figure 1D ). The uptake of 125 I-15-(piodophenyl)-9MPA did not change at the LVH stage and decreased by 36% at the CHF stage compared with the levels in control rats ( Figure 1F ).
Expression of Molecules Related to Energy Metabolism
To examine the mechanisms underlying the change in cardiac energy reserves and substrate uptake, we profiled the expres- DS rats that were fed an HS diet developed hypertension, showing concentric LVH at 11 weeks (W) of age. The rats eventually developed CHF with systolic dysfunction at Ϸ17 weeks of age. DS rats that were fed an LS diet were used as controls. B, PCr/ATP decreased by 12% in LVH rats and 42% in CHF rats compared with control rats; nϭ8 -16 for each group. C, Representative images of myocardial uptake of 18 FDG. D, Uptake of 18 FDG increased by 1.4-fold in LVH rats and 2.4 fold in CHF rats compared with control rats. E, Representative images of myocardial uptake of 125 I-9MPA. F, Uptake of 125 I-9MPA did not change in LVH rats but decreased by 36% in CHF rats; nϭ6 -12. *PϽ0.05 vs control rats.
†PϽ0.05 vs CHF.
sion of molecules related to energy metabolism. The gene expression of glucose transporter 4 was increased at the LVH stage, whereas the expression of glucose transporter 4 was decreased and that of glucose transporter 1 was increased at the CHF stage ( Figure 2A and supplemental Table IV ). The expression of fatty acid transporter was preserved at the LVH stage but decreased at the CHF stage. The gene expression of glycolytic enzymes was preserved at the LVH stage, and levels of some glycolytic enzyme mRNAs were decreased at the CHF stage ( Figure 2A ). We examined the expression of transcription factors that may regulate the expression of glycolytic enzymes. 15, 16 The decrease in glycolytic enzyme mRNAs at the CHF stage seemed to be correlated with the decrease in hypoxia-inducible factor-1␣ protein ( Figure 2B and 2C).
The gene expression of several enzymes related to fatty acid oxidation (FAO) and mitochondrial function was pre-served at the LVH stage but decreased at the CHF stage. 17 The reduction in expression of FAO-related genes was associated with decreased expression of transcriptional regulators of FAO and mitochondrial function (Figure 2A through 2C), such as peroxisome proliferator-activated receptor-␣, peroxisome proliferator-activated receptor-␥ coactivator-1␣, and nuclear respiratory factor 1. 18, 19 Creatine transporter mRNA was decreased at the CHF stage. Shift of the creatine kinase isoform from muscle type to brain type was observed at the CHF stage (Figure 2A ), which is consistent with a previous report. 20 Another key regulator of energy metabolism in the heart is AMP-activated protein kinase. 21 AMP-activated protein kinase is activated by an increase in the AMP-ATP ratio and is thought to be a marker of cellular energy status. Phosphorylated AMP-activated protein kinase, an activated form, increased at the LVH and CHF stages ( Figure 2B and 2C). 22 Figure 2 . Expression of molecules related to energy metabolism during the transition from LVH to CHF. A, Gene expression related to cardiac energy metabolism was measured by quantitative reverse transcription-polymerase chain reaction. 18S rRNA was used as an internal control. B and C, The levels of proteins related to energy metabolism were examined by Western blotting and quantified by densitometry. Hypoxia-inducible factor-1␣, peroxisome proliferator-activated receptor-␥ coactivator-1-␣, and peroxisome proliferatoractivated receptor-␣ were examined in nuclear extracts. Total cell lysate was used for other proteins. The mean value for control rats was expressed as 1 unit. *PϽ0.05 vs control rats. †PϽ0.05 vs LVH rats.
DCA Prevented the Transition From LVH to CHF
To test whether the modulation of cardiac energy metabolism prevents the transition from cardiac hypertrophy to heart failure, the effect of DCA was examined. Long-term administration of DCA starting at 11 weeks of age improved the survival of DS rats that were fed an HS diet ( Figure 3A ). On echocardiographic examination, DCA preserved systolic function as assessed by fractional shortening ( Figure 3B and supplemental Table II ). DCA decreased plasma levels of brain natriuretic peptides at the CHF stage ( Figure 3C ). DCA ameliorated the increase in heart and lung weights of CHF rats ( Figure 3D and supplemental Table V ). DCA attenuated the fibrosis of the myocardium in CHF rats (supplemental Figure IIA and IIB). Very few apoptotic cells were observed in heart tissues of CHF rats, with no difference compared with control rats (supplemental Figure IIC and IID). Thus, DCA preserved cardiac function and prevented CHF. PDH activity in heart tissue was unchanged at the LVH or CHF stage but was increased by DCA ( Figure 3E ). DCA increased PDH activity in cardiomyocytes (supplemental Figure III) . Plasma lactate level Figure 3 . Effects of DCA on CHF rats. A, Administration of DCA or vehicle to DS rats with LVH started from 11 weeks (W) of age. DCA improved the survival of CHF rats. B, Representative images of echocardiography, showing that DCA improved systolic cardiac function. C, DCA attenuated the increase in the plasma concentrations of brain natriuretic peptides at the CHF stage. D, CHF rats showed increased heart weight and lung weight per body weight, and DCA ameliorated the increase. E, PDH activity was unchanged at the LVH or CHF stage and was increased by DCA. Representative images and quantification by densitometry. The mean value for control rats was expressed as 1 unit. F, Plasma lactate and pyruvate levels. *PϽ0.05 vs control rats with vehicle or DCA. †PϽ0.05 vs vehicletreated rats on the same diet. nϭ5-8 for each group. of CHF rats was increased ( Figure 3F and supplemental Table  VI ). DCA lowered plasma lactate and pyruvate levels in HSϩDCA rats, suggesting that DCA activated PDH and facilitated the entry of pyruvate and lactate into cells.
Effects of DCA on Myocardial Energy Reserve and Substrate Uptake
The administration of DCA increased PCr/ATP in rats that were fed an LS or HS diet ( Figure 4A ). Long-term DCA administration increased 18 FDG uptake in normal rats but did not change 125 I-9MPA uptake ( Figure 4B and 4C). DCA tended to decrease 18 FDG uptake and increase 125 I-9MPA uptake in CHF rats. The increased 18 FDG/ 125 I-9MPA of CHF rats was significantly reduced by DCA.
The attenuation of 18 FDG uptake by DCA in CHF rats may be a secondary event due to the improvement of CHF by long-term DCA administration. To examine the direct effect of DCA, we examined the effect of short-term DCA administration on 18 FDG uptake at 11 weeks of age, when DCA administration was started in the long-term experiment. Short-term DCA administration increased the uptake of 18 FDG in both control and hypertrophied hearts ( Figure 4D ). In addition, long-term administration of DCA to control rats increased 18 FDG uptake, PDH activity, and the PCr/ATP, suggesting DCA enhanced glucose oxidation and cardiac energy production. Thus, it is likely that DCA primarily increased glucose oxidation and energy production and ameliorated CHF. DCA attenuated the changes in expression of several genes in CHF hearts ( Figure 5 and supplemental Table IV ). DCA augmented the decrease of peroxisome proliferator-activated receptor-␣ and nuclear receptor factor 1 gene expressions.
Metabolomic Profile of the Transition From Hypertrophy to Heart Failure
We measured the amounts of metabolites from glycolysis and the TCA cycle, as well as nucleotides and amino acids, by capillary electrophoresis time-of-flight mass spectrometry. [23] [24] [25] The results of the quantification of all metabolites examined are listed in supplemental Table VII. The result of the metabolome analysis of glycolysis and the TCA cycle is shown in Figure 6A . Pyruvate increased, alanine decreased, and succinate decreased in the heart tissues of CHF rats. However, it was difficult to estimate the flux of glycolysis or the TCA cycle based on a "snapshot" quantification of the metabolites. The energy metabolism of a cell is regulated at multiple levels, such as gene and protein expression and multiple posttranslational modifications of protein.
Because preservation of energy production is essential to the survival of cells, impairment of the system is compensated for by multiple mechanisms, and the change in the amount of metabolites is smaller than the changes of gene or protein expression of enzymes. 24 Figure 4 . Effects of DCA on myocardial energy reserve and substrate utilization. A, Chronic DCA administration increased cardiac PCr/ ATP in both control and CHF rats. B and C, DCA increased 18 FDG uptake in normal rats but did not change 125 I-9MPA uptake. DCA tended to decrease 18 FDG uptake and increase 125 I-9MPA uptake in CHF rats. The increase of 18 FDG/ 125 I-9MPA in CHF rats was significantly reduced by DCA. *PϽ0.05 vs control rats with vehicle or DCA. †PϽ0.05 vs vehicle-treated rats on the same diet. nϭ6 -10 for LS diet and nϭ16 -19 for HS diet. D, Short-term DCA administration increased 18 FDG uptake in control and LVH rats. *PϽ0.05 vs control rats. †Pϭ0.07 vs vehicle-treated LVH rats; nϭ6 -8.
A pathway in which we could estimate flux was the pentose phosphate pathway (PPP) ( Figure 6B ). The PPP derives from a glycolytic pathway via glucose 6-phosphate, which is also an intermediate of glycolysis. The pathway recycles the reduced form of nicotinamide adenine dinucleotide phosphate (NADPH), which makes reduced glutathione (GSH) to neutralize oxidative stress, thus regulating the cellular redox state. The NADPH/NADP ϩ (oxidized form) increased at the CHF stage and was further increased by DCA. DCA also increased levels of both GSH and oxidized glutathione (GSSG). Moreover, opthalmate is reported to be a sensitive indicator of oxidative stress and is thought to be synthesized through the same by enzymes of glutathione synthesis. 25 Feedback inhibition of opthalmate synthesis by GSH resulted in a reduced level of opthalmate in the reducing state. Our results showed an increase in GSH with a concurrent decrease in opthalmate on DCA treatment.
Confirmation of the Metabolome Analysis
To confirm the results of the metabolome analysis, amounts of metabolites of PPP were measured by enzyme recycling methods (supplemental Figure IVA and IVB) . The NADPH/ NADP ϩ was increased in CHF rats and was increased by DCA in both control and CHF rats. The GSH/GSSG was significantly increased by DCA treatment in CHF rats.
PPP Was Activated at the CHF Stage or by DCA in Rat Hearts
To examine whether the increase in NADPH/NADP ϩ was due to activation of PPP, we examined the gene expression, protein expression, and enzymatic activity of glucose 6-phosphate dehydrogenase (G6PD), a rate-limiting enzyme of PPP in heart tissue. G6PD activity was increased at the CHF stage or by DCA ( Figure 7A ). Inhibition of G6PD by dehydroepiandrosterone (DHEA) sulfate attenuated the DCA-induced increase in NADPH/NADP ϩ , suggesting DCA increased the ratio by activating PPP (Figure 7B ).
DCA Reduced Oxidative Stress in DS Rat Hearts
Because the increase in NADPH and GSH reduces oxidative stress and oxidative stress is implicated in CHF, 26 we examined the effect of DCA on markers of oxidative stress. Thiobarbituric acid-reactive substances (TBARS), a marker of lipid peroxidation, increased at the CHF stage, and DCA attenuated the increase ( Figure 7C ). The amount of 4-hydroxy-2-nonenal-modified proteins, an index of protein peroxidation, increased at the CHF stage, and DCA attenuated the increase ( Figure 7D ).
DCA Attenuated Myocyte Cell Death in a PPP-Dependent Manner
Next, we investigated the effect of DCA on the survival of cultured myocytes. DCA protected myocytes in a dosedependent manner from H 2 O 2 -induced cell death ( Figure 8A ). Pharmacologic inhibition of G6PD with DHEA or 6-aminonicotinamide indicated the protective effect of DCA to be dependent on PPP ( Figure 8B ). Small interfering RNAs of G6PD also abolished the protective effect of DCA (supplemental Figure VA and VB). DCA increased G6PD activity, NADPH/NADP ϩ , and GSH/GSSG, and the increases were attenuated by inhibitors ( Figure 8C 
Discussion
In this study, we characterized metabolic remodeling in compensated LVH and CHF. LVH or CHF was associated with a distinct change in the metabolic profile of the heart. DCA increased glucose uptake and cardiac energy reserves and ameliorated CHF. Thus, alteration of cardiac energy metabolism is not an epiphenomenon but a cause of CHF, and long-term administration of DCA may be a useful therapeutic modality for CHF. The metabolome analysis indicated activation of PPP in CHF. PPP was also activated by DCA, and DCA protected myocytes from oxidative stress-induced cell death, suggesting activation of PPP by increased glucose metabolism to be a protective mechanism in CHF. NADPH increases were associated with increased G6PD activity at the CHF stage, suggesting that the flux of PPP was increased. DCA also increased G6PD activity and increased NADPH and GSH levels in a G6PD-dependent manner in rat hearts. G6PD protected cardiac myocytes from H 2 O 2 -induced cell death dependent on PPP. In addition, mice with reduced levels of G6PD activity developed cardiac dysfunction through increased susceptibility to reactive oxygen species. 27 Thus, activation of G6PD at the CHF stage is likely to be an adaptive mechanism. The mechanism by which CHF increases G6PD activity is unclear. Oxidative stress increased G6PD activity in the heart. 27 In addition, induction of mitochondrial dysfunction is associated with increased flux of glycolysis and PPP, 28 in which the amounts of pyruvate and metabolites of PPP derived from isotope-labeled glucose increased. Indeed, the expression of genes and transcriptional regulators of mitochondrial function was decreased in our study, and reduced mitochondrial function in failing hearts has been reported. 26 In our study, pyruvate was increased in CHF rat hearts. Enhanced glycolysis may produce more pyruvate than is used in diseased mitochondria and thus cause pyruvate to accumulate. The mechanism by which DCA increased G6PD activity and PPP also needs to be clarified. The increase of GSH by DCA in cardiomyocytes has been reported. 29 One purpose of this study was to obtain a comprehensive metabolic profile of compensated LVH and decompensated heart failure in an in situ condition, because energy metabolism of a cell is highly dependent on the environment 24 and Figure 7 . G6PD was activated at the CHF stage or by DCA. A, Gene and protein expressions of G6PD did not differ between the groups. The G6PD activity was increased at the CHF stage or by DCA. The mean value for control rats was defined as 1 unit; nϭ6 -8 for each group. *PϽ0.05 vs control rats with vehicle or DCA. †PϽ0.05 vs vehicle-treated rats on the same diet. #PϽ0.05 vs LVH rats. B, DHEA sulfate decreased G6PD activity and NADPH/NADP ϩ in rats administered DCA; nϭ5. *PϽ0.05 vs rats without DCA. †PϽ0.05 vs rats without DHEA sulfate. C, Myocardial TBARS did not change at the LVH stage but increased at the CHF stage. DCA decreased TBARS of CHF rats; nϭ6 -8. *PϽ0.05 vs control rats with vehicle or DCA. †PϽ0.05 vs vehicle-treated rats on the same diet. D, 4-Hydroxy-2-nonenal-modified protein was increased in CHF rats, and the increase was attenuated by DCA. A representative blot is shown, and GAPDH was used as a loading control.
the results obtained from experiments in ex vivo perfused hearts are highly dependent on the substrate in the perfusion buffer, work load, and differences in cardiac function between control and failing hearts. 30 Glucose uptake was significantly increased at the CHF stage. However, it is unclear how this glucose was metabolized in this study.
Glucose is converted to pyruvate via glycolysis, and pyruvate is metabolized in the mitochondria by oxidation, namely, glucose oxidation. Glucose is also metabolized via other pathways, such as PPP. In humans or large animals, glucose metabolism in the heart can be measured in situ by infusing isotope-labeled glucose and collecting blood samples from the coronary sinus or by using multiple cardiac substrates labeled with positron-emitting isotopes. Although it is difficult to measure glucose metabolism in situ in the hearts of small animals, we speculate that glycolysis was increased in CHF rat hearts in the presence of decreased gene expression of glycolytic enzymes for the following reasons. First, the gene expression of glycolytic enzymes is paradoxically downregulated in the presence of enhanced glucose oxidation in a canine model of heart failure. 31 Second, the gene expression of glycolytic enzymes is decreased in failing human hearts, 32 and glucose metabolism is increased in failing human hearts. 33 Third, using ex vivo perfused heart preparations, several investigators found glycolysis to be increased in hypertrophied hearts of small animals. 34, 35 However, whether increased glycolysis is coupled to glucose oxidation is controversial, 35 and the increase in pyruvate at the CHF stage may indicate that glycolysis increased, independent of glucose oxidation. In addition, it is also likely that increased glucose uptake reflects increased glucose metabolism other than glucose oxidation, such as PPP. The fate of glucose needs to be determined in future studies by injecting isotope-labeled glucose and measuring metabolites. 36, 37 We performed a metabolome analysis by capillary electrophoresis time-of-flight mass spectrometry. Unfortunately, we could not determine the amounts of metabolites in fatty acid metabolism because they are electronically uncharged and cannot be separated by electrophoresis. However, we speculate that FAO was decreased at the CHF stage because the expression of genes and proteins related to FAO and mitochondrial function was decreased, fatty acid uptake decreased, and the PCr/ATP was significantly decreased. In addition, decreased FAO has been consistently reported in animal models of CHF and in patients with CHF. 2, 30, 33 Recently, Pound et al 38 reported that DCA increased glucose oxidation and improved cardiac contractility of ex vivo perfused hypertrophied hearts. In that study, they showed that carboxylation of pyruvate via a cytosolic malic enzyme instead of PDH produced a malate and enabled the anaplerotic influx of carbon into the TCA cycle. The anaplerotic flux through malic enzyme consumes NADPH. Pound et al reported that malate increased in hypertrophied hearts, but malate levels did not change at the LVH or CHF stage in our study. The difference may be due to the experimental conditions used. NADPH increased, rather than decreased, in our study, suggesting PPP to be a major source of NADPH in cells. 39 Because the oxygen consumption of LVH hearts in this rat model is significantly increased, 40 the mild decrease of energy reserves in situ may be due to an increase in energy consumption rather than a decrease in energy production. LVH was associated with unchanged fatty acid uptake, increased glucose uptake, and preserved gene and protein expression related to FAO and mitochondrial function, suggesting that an alteration of energy metabolism at the LVH stage largely depended on posttranscriptional mechanisms. At the CHF stage, oxygen consumption was decreased 40 and cardiac energy reserve was markedly decreased, suggesting that energy production was likely to be decreased. CHF is associated with decreased fatty acid uptake, a further increase in glucose uptake, and increased reactive oxygen species production. Because a global change in gene expression related to energy production was a characteristic of the CHF stage, transcriptional regulation may be important in metabolic remodeling during the transition from LVH to CHF. It may be hypothesized that decreased expression of genes related to mitochondrial function causes a significant reduction in energy reserves and enhances glycolysis via a posttranscriptional mechanism, such as the Randlel reaction, to compensate for the decreased energy reserves. The increased glucose metabolism may also attenuate oxidative stress by activating PPP. Further studies are needed to test this hypothesis.
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CLINICAL PERSPECTIVE
Congestive heart failure (CHF) is associated with a significant change in energy metabolism of the heart, and this alteration has been hypothesized to be important in the progression of CHF. Because treatment that improves the prognosis of patients with CHF, such as with ␤-adrenergic receptor blockers or angiotensin-converting enzyme inhibitors, is energy-sparing, it is hoped that modulation of cardiac energy metabolism may ameliorate CHF. We analyzed cardiac energy metabolism in Dahl salt-sensitive rats that were fed a high-salt diet, which showed a transition from compensated left ventricular hypertrophy to CHF. Left ventricular hypertrophy or CHF was associated with a distinct change in the metabolic profile of the heart. Glucose uptake increased and fatty acid uptake decreased in CHF. On comprehensive metabolome analysis that simultaneously measured the levels of multiple metabolites in heart tissue, the pentose phosphate pathway that regulates the cellular redox state was found to be activated in CHF. Dichloroacetate, a compound known to enhance glucose oxidation, increased glucose uptake and the energy reserve and improved cardiac function and survival. Dichloroacetate also activated the pentose phosphate pathway, decreased oxidative stress, and prevented cell death of cultured cardiomyocytes. Thus, increased glucose metabolism in CHF is likely to act as a protective mechanism by increasing the energy reserve and decreasing oxidative stress via pentose phosphate pathway activation. In summary, modulating the energy metabolism of the heart is likely to be a promising modality of CHF treatment.
